Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. - Wikidata - awgldk - TriplyDB

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

http://www.wikidata.org/entity/Q33249551

about

Non-Covalent Derivatives: Cocrystals and Eutectics Crystallization of Carbamazepine in Proximity to Its Precursor Iminostilbene and a Silica Surface Small-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration.Acemetacin cocrystals and salts: structure solution from powder X-ray data and form selection of the piperazine salt The challenging case of the theophylline-benzamide cocrystal.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles The effect of microcrystalline cellulose crystallinity on the hydrophilic property of tablets and the hydrolysis of acetylsalicylic acid as active pharmaceutical ingredient inside tablets.2-(1,3-Dioxoisoindolin-2-yl)acetic acid-N'-[(E)-2-meth-oxy-benzyl-idene]pyridine-4-carbohydrazide (1/1).Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5 Crystal engineering of green tea epigallocatechin-3-gallate (EGCg) cocrystals and pharmacokinetic modulation in rats.Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents.Pharmaceutical Cocrystals and Their Physicochemical Properties.Benefits of cocrystallisation in pharmaceutical materials science: an update.Cocrystallization for successful drug delivery.Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics.Solution-mediated phase transformation of haloperidol mesylate in the presence of sodium lauryl sulfate.The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: crystalline and semi-crystalline carriers.In vitro/in vivo evaluation of an optimized fast dissolving oral film containing olanzapine co-amorphous dispersion with selected carboxylic acids.Influence of sodium lauryl sulfate and tween 80 on carbamazepine-nicotinamide cocrystal solubility and dissolution behaviour.Solid-State Characterization and Interconversion of Recrystallized Amodiaquine Dihydrochloride in Aliphatic Monohydric Alcohols.Application of twin screw extrusion in the manufacture of cocrystals, part I: four case studies.Evaluation of Influence of Various Polymers on Dissolution and Phase Behavior of Carbamazepine-Succinic Acid Cocrystal in Matrix Tablets.Bioavailability of indomethacin-saccharin cocrystals.Crystal engineering to improve physicochemical properties of mefloquine hydrochloride.Detection of cocrystal formation based on binary phase diagrams using thermal analysis.Simultaneously improving the mechanical properties, dissolution performance, and hygroscopicity of ibuprofen and flurbiprofen by cocrystallization with nicotinamide.Enhancing the solubility and masking the bitter taste of propiverine using crystalline complex formation.Effect of cocrystallization techniques on compressional properties of caffeine/oxalic acid 2:1 cocrystal.Application of twin screw extrusion to the manufacture of cocrystals: scale-up of AMG 517-sorbic acid cocrystal production.Proton transfer and hydrogen bonding in the organic solid state: a combined XRD/XPS/ssNMR study of 17 organic acid-base complexes.Preparation and Characterization of Cabamazepine Cocrystal in Polymer Solution.Mechanistic Basis of Cocrystal Dissolution Advantage.Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs.Outlook on the Application of Metal-Liganded Bioactives for Stimuli-Responsive Release.Comparison of the relative stability of pharmaceutical cocrystals consisting of paracetamol and dicarboxylic acids.Mechanochemical preparation of co-crystals.Solubility and dissolution enhancement strategies: current understanding and recent trends.The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance.

P2860

Q26796674-66BA7A67-93D8-4A58-9E03-DB5BEE135A90 Q28833259-E9EC0EA8-2308-4978-8981-C24D9D99A13F Q30375810-DD4E44F7-A361-4A71-806A-112075748964 Q30839515-08D3B563-2503-4D93-A511-53D108EAF40B Q31052880-5DCF0593-0E63-422C-9D5E-C346D85393BC Q33683206-4A74847B-B911-4034-94F3-D268E066338C Q35868353-B9710C2C-95C3-4B46-B377-3C74830737A5 Q36149112-D7733D84-5E5B-420F-8B72-7A17E507BD66 Q36446679-00FB6B71-1A70-4C12-8B14-7246A5B5C49E Q36666790-8C11644F-CEA1-4040-A2F2-22B52F7450AC Q37013110-BE6F1C10-2872-4CA1-94ED-7042A4D51024 Q37226778-6B8311C7-C317-494D-A53A-B1D14E81733A Q37415146-37C9ECBC-CD30-4B23-AE2F-9DAC7E570DCC Q37510600-E5C37932-0CBC-4794-8B68-2EF143782111 Q37805586-FF824ABA-B0FA-47C1-BDDC-EFDE3BE345DC Q38068972-C0B9D153-C4FB-497B-9398-ADDF66A58E97 Q38236638-2DD91188-5E02-42C5-8E40-CA2B4154B005 Q38312371-F99D7C09-1B7F-435C-9428-B85EEB4DB78C Q38870191-F897543E-9FEA-4BD8-A04E-962BC714C024 Q39934188-AE043102-BE57-4CE7-A73A-52E091C50BD7 Q41869235-F962682A-8152-4CB1-8715-DDAF850CDF1A Q41987417-19F67FE4-E329-4C92-A5B7-6A909BFC0E85 Q42114331-9C9FB049-D577-4B78-82B5-F760DEF03F8D Q42581894-1AE6C2A2-36DD-4288-B47E-206F91C70861 Q42840455-D56D8D10-C31F-4F8C-AA67-631F812A30A9 Q43119928-693BF739-F29E-4352-BCAD-CF0E180A438E Q43787861-DD27F631-EDAE-4A81-9B34-E02736AF1AF8 Q44493438-017217C1-40FF-4282-99E4-C54AE2CAE40D Q44554881-94263275-1FFE-4AA8-948E-D8FC47F9677B Q46035457-2382E29D-BBF9-4934-B0B6-A29B4D93FD16 Q46955396-E98963E4-58DD-45F8-B2B4-59F96142C624 Q46965118-6AEF1784-25C4-4D04-A9A1-D0456A447A1B Q47294973-0E65AF46-796B-430D-AE3F-31F7985016CD Q47657942-F683DBD9-27FE-4CCA-8911-DECA42DD7133 Q48166645-7D320FCE-A8B7-4143-A7F5-523510C64B91 Q48216763-4E2DE15D-0FA8-43DF-A882-C5B41F35DB7C Q48314127-8F5E01BD-A6D1-480B-8836-EFC1F70BE604 Q50482233-B34B6747-54F3-4D87-8ACA-8AB690143A39 Q51020710-762266A0-AAD1-45A9-973B-2C3FDD63F82F Q51688735-4EA74B42-C494-4A7A-A18A-D4CC89471B47

P2860

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

http://www.wikidata.org/entity/Q33249551

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

@ast

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

@en

type

label

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

@ast

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

@en

prefLabel

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

@ast

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

@en

P1433

Q33249551-A3E6899D-0075-49EB-9262-B2C988D6B467

P1476

Q33249551-0D05A0B0-41BC-42E6-9F4F-A26A44929AEC

P2093

Q33249551-185A9471-E840-473A-96B8-ED13D8FC6A50

Q33249551-24156412-B4DF-40F4-9F30-DF7F561ED8A4

Q33249551-30361A17-2E19-409D-8473-E8C272C0CD66

Q33249551-439F4021-8722-49BD-A215-F4D78450B2FB

Q33249551-5BF6DC4F-8066-4F27-BDA5-140293FA7B87

Q33249551-70CD1FDE-1309-4FF8-B558-49166449B2C9

Q33249551-AECF3F4D-0016-4A46-A86C-712CA43E78A9

Q33249551-B4750183-F527-41F3-9C85-54650C90DB52

Q33249551-F3832B76-887D-458B-84DF-810A3C758AD9

P304

Q33249551-C4F9135A-F906-4D01-BF23-40B4651E4E93

P31

Q33249551-544453EA-A4B5-44BA-9F8B-1C4775C8B653

P356

Q33249551-0BF1ECEE-09E8-4C38-AC86-DD9B9055FBCF

P433

Q33249551-3F7EA38F-2926-420F-99BA-93D44D2060F7

P478

Q33249551-787DF859-81E5-4BB3-989E-9074E4EE7AC4

P577

Q33249551-A37C1DF7-86DE-42C8-BC89-26EB2DC9BC15

P5875

Q33249551-7D2A9F8A-B0B2-4611-9308-DCD43E8823D8

P698

Q33249551-8CFBB2A8-E1DE-462C-9351-D222358739D2

P356

S11095-006-9032-3

P1433

Pharmaceutical Research

P1476

Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.

@en

P2093

Aeri Park

http://www.w3.org/2001/XMLSchema#string

Anthony Iarriccio

http://www.w3.org/2001/XMLSchema#string

Daniel P McNamara

http://www.w3.org/2001/XMLSchema#string

Ed O'Donnell

http://www.w3.org/2001/XMLSchema#string

James Cassidy

http://www.w3.org/2001/XMLSchema#string

Jennifer Giordano

http://www.w3.org/2001/XMLSchema#string

Manjunath S Shet

http://www.w3.org/2001/XMLSchema#string

Richard Mannion

http://www.w3.org/2001/XMLSchema#string

Scott L Childs

http://www.w3.org/2001/XMLSchema#string

P304

1888-1897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-006-9032-3

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6952269

http://www.w3.org/2001/XMLSchema#string

P698

16832611

http://www.w3.org/2001/XMLSchema#string